New hope for tough esophageal cancer: HS-20093 enters final trial

NCT ID NCT07621601

Not yet recruiting Disease control Sponsor: Hansoh BioMedical R&D Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will receive either HS-20093 or one of three standard chemo drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20093 (Risvutatug Rezetecan)
What this could lead to: If successful, this could offer a new treatment option for people with advanced esophageal cancer that has stopped responding to initial therapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not improve survival or could have side effects like other chemotherapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.